GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzinova AB (OSTO:ALZ) » Definitions » Float Percentage Of Total Shares Outstanding

Alzinova AB (OSTO:ALZ) Float Percentage Of Total Shares Outstanding : 0.00% (As of Apr. 30, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Alzinova AB Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alzinova AB's float shares is 0.00 Mil. Alzinova AB's total shares outstanding is 44.53 Mil. Alzinova AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alzinova AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alzinova AB's Institutional Ownership is 0.01%.


Alzinova AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Alzinova AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/44.53
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzinova AB (OSTO:ALZ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzinova AB (OSTO:ALZ) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
Pepparedsleden 1, Molndal, SWE, SE-431 83
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is also engaged in development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody. The product is in clinical development as a therapeutic vaccine for the treatment of Alzheimer's.

Alzinova AB (OSTO:ALZ) Headlines

No Headlines